In addition, human CCL5 was identified as a novel, direct target of miR‐146a.26 Aside from the NF‐κB pathway, a recent study reported the existence of a negative correlation between serum miR‐146a and IgE levels in patients with allergic‐type AD that is characterized by strong type‐2‐cell‐mediated immune response and remarkably high level of IgE in serum.27 Taken together, miR‐146a could limit NF‐κB‐dependent inflammatory reaction and type‐2‐cell‐mediated immune responses in AD. This evidence concerns the gene NFKB1 and Alzheimer disease.